News
In recent trading, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) have crossed above the average analyst 12-month target price of $509.33, changing hands for $509.47/share. When a stock ...
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of ...
Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded ...
Several catalysts in 2025 support a bullish outlook for the pharma stock. Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta ...
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results tomorrow afternoon. Here’s what investors should know. Vertex Pharmaceuticals beat analysts’ revenue ...
Vertex Pharmaceuticals VRTX will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Vertex ...
Vertex Pharmaceuticals Inc. closed 5.66% below its 52-week high of $519.88, which the company reached on November 8th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback